Nitric oxide affects IL-6 expression in human peripheral blood mononuclear cells involving cGMP-dependent modulation of NF-κB activity

Cytokine

Volumn 54, Issue 3, 2011, Pages 282-288

  Siednienko, Jakub ^a,b   Nowak, Joanna ^a   Moynagh, Paul N ^b   Gorczyca, Wojciech A ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

CGMP; IL 6; NF B; Nitric oxide; PBMC

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 8 BROMO CYCLIC GMP; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GUANYLATE CYCLASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; KT 5823; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; S NITROSOGLUTATHIONE;

ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARBAZOLES; CELL NUCLEUS; CYCLIC GMP; CYTOKINES; GENETIC VECTORS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; S-NITROSOGLUTATHIONE;

EID: 79955143266     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.02.015     Document Type: Article

References (47)

1. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic and joint destruction. Autoimmun Rev 2009, 8:538-542.
2. Korhonen R., Lahti A., Kankaanranta H., Moilanen E. Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Alergy 2005, 4:471-479.
3. Ongini E., Impagnatiello F., Bonazzi A., Guzzeta M., Govoni M., Monopoli A., et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 2004, 101:8497-8502.
4. Turnbull C.M., Marcarino P., Sheldrake T.A., Lazzarato L., Cena C., Fruttero R., et al. A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages. J Inflamm 2008, 5:12.
5. Yip K.H., Huang Y., Leung F.P., Lau H.Y. Cyclic guanosine monophosphate dependent pathway contributes to human mast cell inhibitory actions of the nitric oxide donor, diethylamine NONOate. Eur J Pharmacol 2010, 32:86-92.
6. Makris A.C., Sotzios Y., Zhou Z., Makropoulou M., Papapetropoulos N., Zacharatos P., et al. Nitric oxide stimulates interleukin-6 production in skeletal myotubes. Interferon Cytokine Res 2010, 30:321-327.
7. Lander H.M., Sehajpal P.S., Levine D.M., Novogrodsky A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol 1993, 150:1509-1516.
8. Yoshioka Y., Takeda N., Yamamuro A., Kasai A., Maeda S. Nitric oxide inhibits lipopolysaccharide-induced inducible nitric oxide synthase expression and its own production through the cGMP signaling pathway in murine microglia BV-2 cells. J Pharmacol Sci 2010, 113:153-160.
9. Morita R., Uchiyama T., Hori T. Nitric oxide inhibits IFN-α production of human plasmacytoid dendritic cells partly via a guanosine 3′,5′-cyclic monophosphate-dependent pathway. J Immunol 2005, 175:806-812.
10. Connelly L., Palacios-Callender M., Ameixa C., Moncada S., Hobbs A.J. Biphasic regulation of NF-κB activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol 2001, 166:3873-3881.
11. Braam B., de Roos R., Dijk A., Boer P., Post J.A., Kemmeren P.P.C.W., et al. Nitric oxide donor induces temporal and dose-dependent reduction of gene expression in human endothelial cells. Am J Physiol Heart Circ Physiol 2004, 287:H1977-H1986.
12. Macphail S.E., Gibney C.A., Brooks B.M., Booth C.G., Flanagan B.F., Coleman J.W. Nitric oxide regulation of human peripheral blood mononuclear cells: critical time dependence and selectivity for cytokine versus chemokine expression. J Immunol 2003, 171:4809-4815.
13. Lopez A.S., Alegre E., Diaz A., Mugueta C., Gonzalez A. Bimodal effect of nitric oxide in the enzymatic activity of indoleamine 2,3-dioxygenase in human monocytic cells. Immunol Lett 2006, 106:163-171.
14. Mancini L., Moradi-Bidhendi N., Becherini L., Martineti V., MacIntyre I. The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent. Biochem Biophys Res Commun 2000, 274:477-481.
15. Ziolo M. The fork in the nitric oxide road: cyclic GMP or nitrosylation?. Nitric Oxide 2008, 18:153-156.
16. Roy A., Fung Y.K., Liu X., Pahan K. Up-regulation of microglial CD11b expression by nitric oxide. J Biol Chem 2006, 281:14971-14980.
17. Katsuyama K., Schichiri M., Marumo F., Hirata Y. NO inhibits cytokine-induced iNOS expression and NF-κB activation by interfering with phosphorylation and degradation of IκB-α. Arterioscler Thromb Vasc Biol 1998, 18:1796-1802.
18. Giordano D., Magaletti D.M., Clark E.A. Nitric oxide and cGMP protein kinase (cGK) regulate dendritic-cell migration toward the lymph-node-directing chemokine CCL19. Blood 2006, 107:1537-1545.
19. Gomes B., Savignac M., Cabral M.D., Paulet P., Moreau M., Leclerc C., et al. The cGMP/protein kinase G pathway contributes to dihydropyridine-sensitive calcium response and cytokine production in Th2 lymphocytes. J Biol Chem 2006, 281:1241-1247.
20. Kalra D., Baumgarten G., Dibbs Z., Seta Y., Sivasubramanian N., Mann D.L. Nitric oxide provokes tumor necrosis factor-α expression in adult feline myocardium through a cGMP-dependent pathway. Circulation 2000, 102:1302-1307.
21. Wong D., Prameya R., Wu V., Dorovini-Zis K., Vincent S.R. Nitric oxide reduces T lymphocyte adhesion to human brain microvessel endothelial cells via a cGMP-dependent pathway. Eur J Pharmacol 2005, 514:91-98.
22. Kallmann B.A., Malzkorn R., Kolb H. Exogenous nitric oxide modulates cytokine production in human leukocytes. Life Sci 1999, 65:1787-1794.
23. Ahluwalia A., Foster P., Scotland R.S., McLean P.G., Mathur A., Perretti M., et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 2003, 101:1386-1391.
24. Broderick K.E., Zhang T., Rangaswami H., Zeng Y., Zhao X., Boss G.R., et al. Guanosine 3′,5′-cyclic monophosphate (cGMP)/cGMP-dependent protein kinase induce interleukin-6 transcription in osteoblasts. Mol Endocrinol 2007, 21:1148-1162.
25. Bryan N.S., Bian K., Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci 2009, 14:1-18.
26. Ciuman M., Siednienko J., Czyżyk R., Witwicka H., Kołosionek E., Kobiałka M., et al. Cyclic GMP-dependent protein kinase and soluble guanylyl cyclase disappear in elicited rat neutrophils. Biochim Biophys Acta 2006, 1760:1618-1623.
27. Kurowska E., Kobiałka M., Zioło E., Strzaogonekdała L., Gorczyca W.A. The cGMP synthesis and PKG1 expression in murine lymphoid organs. Arch Immunol Exp Ther 2002, 50:289-294.
28. Fischer T.A., Palmetshofer A., Gambaryan S., Butt E., Jassoy C., Walter U., et al. Activation of cGMP-dependent protein kinase Iβ inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells. J Biol Chem 2001, 276:5967-5974.
29. Pryzwansky K.B., Kidao S., Wyatt T.A., Reed W., Lincoln T.M. Localization of cyclic GMP-dependent protein kinase in human mononuclear phagocytes. J Leukoc Biol 1995, 57:670-678.
30. Bonizzi G., Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25:280-288.
31. Gloire G., Legrand-Poels S., Piette J. NF-κB activation by oxygen species: fifteen years later. Biochem Pharmacol 2006, 72:1493-1505.
32. Bureau F., Vanderplasschen A., Jaspar F., Minner F., Pastoret P.-P., Merville M.-P., et al. Constitutive nuclear factor-κB activity preserves homeostasis of quiescent expression of distinct Bcl-2 family proteins. Blood 2002, 99:3683-3691.
33. Chang M.-S., Lee W.-S., Chen B.-C., Sheu J.-R., Lin C.-H. YC-1-induced cyclooxygenase-2 expression is mediated by cGMP-dependent activation of Ras, phosphoinositide-3-OH-kinase, Akt, and nuclear factor-κB in human pulmonary epithelial cells. Mol Pharmacol 2004, 66:561-571.
34. Chen C.H., Chuang J.H., Liu K., Chan J.Y. Nitric oxide triggers delayed anesthetic preconditioning-induced cardiac protection via activation of nuclear factor-kappaB and upregulation of inducible nitric oxide synthase. Shock 2008, 30:241-249.
35. Eriksson P., Andersson C., Ekerfelt C., Ernerudth J., Skogh T. Sjögren syndrome with myalgia is associated with subnormal secretion of cytokines by peripheral blood mononuclear cells. J Rheumatol 2004, 31:729-735.
36. Zabłocka A., Siednienko J., Mitkiewicz M., Gorczyca W.A., Lisowski J., Janusz M. Proline-rich polypeptide complex (PRP) regulates secretion of inflammatory mediators by its effect on NF-κB activity. Biomed Pharmacother 2010, 64:16-20.
37. Siednienko J., Jankowska E.A., Banasiak W., Gorczyca W.A., Ponikowski P. Nuclear factor-κB activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. Int J Cardiol 2007, 122:111-116.
38. Siednienko J., Halle A., Nagpal K., Golenbock D.T., Miggin S.M. TLR3 mediated IFN-β gene induction is negatively regulated by the TLR adaptor Mal. Eur J Immunol 2010, 40:3150-3160.
39. Pilz R., Casteel D.E. Regulation of gene expression by cyclic GMP. Circ Res 2003, 93:1034-1046.
40. Andoh T., Chiueh C.C., Chock P.B. Cyclic GMP-dependent protein kinase regulates the expression of thioredoxin and thioredoxin peroxidase-1 during hormesis in response to oxidative stress-induced apoptosis. J Biol Chem 2003, 278:885-890.
41. He B., Weber G.F. Phosphorylation of NF-κB proteins by cyclic GMP-dependent kinase. A noncanonical pathway to NF-κB activation. Eur J Biochem 2003, 270:1-12.
42. Connelly L., Jacobs A.T., Palacios-Callender M., Moncada S., Hobbs A.J. Macrophage endothelial nitric-oxide synthase auto-regulates cellular activation and pro-inflammatory protein expression. J Biol Chem 2003, 278:26480-26487.
43. Yoshioka Y., Yamamuro A., Maeda S. Nitric oxide at a low concentration protects murine macrophage RAW264 cells against nitric oxide-induced death via cGMP signaling pathway. Br J Pharmacol 2003, 139:28-34.
44. Marshall H.E., Stamle J.S. Inhibition of NF-κB by S-nitrosylation. Biochemistry 2001, 40:1688-1693.
45. Xie Q.W., Kashiwabara Y., Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994, 269:4705-4708.
46. Marshall H.E., Hess D.T., Stamler J.S. S-nitrosylation: physiological regulation of NF-κB. Proc Natl Acad Sci USA 2004, 101:8841-8842.
47. Kelleher Z.T., Matsumoto A., Stamler J.S., Marshall H.E. NOS2 regulation of NF-κB by S-nitrosylation of p65. J Biol Chem 2007, 282:30667-30672.